infoVAXX
Informative posters and brochures
Vaccination for young people aged 12-17 years (LB - FR - DE) (Pdf, 391 Kb)
Important information after vaccination (FR - DE - LU - EN - PT) (Pdf, 724 Kb)
We are vaccinated. And you? (LU – FR) (Pdf, 657 Kb)
Flyer: 5 reasons to get vaccinated now (LB - FR - DE - EN - PT) (Pdf, 663 Kb)
Posters and brochures in other languages (website of the ONA)
Not without my doctor - Poster (EN - FR - LB - PT) (Pdf, 792 Kb)
Not without my pharmacist - Poster (EN - FR - LB - PT) (Pdf, 2.66 Mb)
Social Media Kit
Publications
Report on the effectiveness of vaccination against COVID-19 in Luxembourg (French, Pdf, 3.60 Mb)
Pharmacovigilance
Report 1 COVID-19 - Monitoring Adverse Vaccine Events (16/04/2021) (French, Pdf, 1.08 Mb)
Report 2 COVID-19 - Monitoring Adverse Vaccine Events (14/05/2021) (French, Pdf, 836 Kb)
Report 3 COVID-19 - Monitoring Adverse Vaccine Events (16/06/2021) (French, Pdf, 1.09 Mb)
Report 4 COVID-19 - Monitoring Adverse Vaccine Events (14/07/2021) (French, Pdf, 1.73 Mb)
Report 5 COVID-19 - Monitoring Adverse Vaccine Events (17/09/2021) (French, Pdf, 1.76 Mb)
Report 6 COVID-19 - Monitoring Adverse Vaccine Events (15/10/2021) (French, Pdf, 1.21 Mb)
Report 7 COVID-19 - Monitoring Adverse Vaccine Events (18/11/2021) (French, Pdf, 1.21 Mb)
Report 8 COVID-19 - Monitoring Adverse Vaccine Events (17/12/2021) (French, Pdf, 797 Kb)
Report 9 COVID-19 - Monitoring Adverse Vaccine Events (21/01/2022) (French, Pdf, 844 Kb)
Report 10 COVID-19 - Monitoring Adverse Vaccine Events (11/02/2022) (French, Pdf, 1.25 Mb)
Report 11 COVID-19 - Monitoring Adverse Vaccine Events (13/04/2022) (French, Pdf, 1.26 Mb)
Report 12 COVID-19 - Monitoring Adverse Vaccine Events (22/06/2022) (French, Pdf, 834 Kb)
Report 13 COVID-19 - Monitoring Adverse Vaccine Events (04/08/2022) (French, Pdf, 1.27 Mb)
Report 14 COVID-19 - Monitoring Adverse Vaccine Events (18/10/2022) (French, Pdf, 1.24 Mb)
Report 15 COVID-19 - Monitoring Adverse Vaccine Events (06/12/2022) (French, Pdf, 1.27 Mb)
Report 16 COVID-19 - Monitoring Adverse Vaccine Events (23/03/2023) (French, Pdf, 931 Kb)
Report 17 COVID-19 - Monitoring Adverse Vaccine Events (02/08/2023) (French, Pdf, 1.19 Mb)
Summary of product characteristics and package leaflet
The vaccines utilized in Luxembourg to help preventing COVID-19 disease have been thoroughly assessed by the European Medicines Agency (EMA) and consequently been approved by the European Commission (EC).
To allow insight into all the information available for the vaccines, the EMA has published a set of important data pertaining to it, including the package leaflet. Following are the various links to the vaccines being distributed in Luxembourg. If you click on the links, you are directed to a dedicated product page on the EMA website. If you scroll down to the heading "Product Information" and click on the respective language (available in 24 different languages), a PDF opens in a new page. In this PDF, you will have access to the package leaflet by scrolling down to section ANNEX III B.
Biontech Pfizer / Comirnaty
Comirnaty | European Medicines Agency (europa.eu)
Moderna / Spikevax
Spikevax | European Medicines Agency (europa.eu)
AstraZeneca / Vaxzevria
Vaxzevria | European Medicines Agency (europa.eu)
JCOVDEN (previously COVID-19 Vaccine Janssen)
Jcovden | European Medicines Agency (europa.eu)
Novavax / Nuvaxovid
Newsletter: Vaccination COVID-19
French version
German version
Videos
Last update